Therapeutic Efficacy of Fluocinolone Acetonide Ointment and Cream

Bleiberg, Jacob

doi:10.1001/archderm.1964.01590280061012

Cited by 3 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FA is a medium potency corticosteroid that has been used in dermatological practice [35]. The insert FAi and the implant FAc, both contain FA, have demonstrated efficacy in the treatment of ocular inflammation and ME secondary to various retinal vascular diseases ( Table 2).…”

Section: Expert Opinionmentioning

confidence: 99%

Sustained-release fluocinolone acetonide intravitreal insert for macular edema: clinical pharmacology and safety evaluation

Sadiq¹,

Agarwal²,

Soliman³

et al. 2015

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

The FAc, Retisert is a sustained-release device that is surgically implanted in the vitreous and has been approved by the US FDA for the treatment of non-infectious intermediate, posterior or panuveitis. FAi was developed after FAc and is an intravitreal corticosteroid delivery system that allows controlled release of therapeutic levels of fluocinolone acetonide (FA). Initial efficacy and safety data suggest that this delivery system maintains clinical effectiveness for up to 3 years after a single delivery of the device. This second-generation fluocinolone delivery device has shown superior safety results in clinical trials compared to the previous version of the higher dose FAc (0.59 mg). Sustained delivery preparations may help to reduce the treatment burden and its associated risks by decreasing the frequency of intravitreal injections. However, much needs to be learnt from additional clinical trials, post-marketing surveillance and results of extension studies. Concerns of intravitreal corticosteroids, such as cataract and increase in intraocular pressure, remain major challenges for this therapeutic strategy.

show abstract

Section: Expert Opinionmentioning

confidence: 99%

Sustained-release fluocinolone acetonide intravitreal insert for macular edema: clinical pharmacology and safety evaluation

Sadiq¹,

Agarwal²,

Soliman³

et al. 2015

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

show abstract

“…(3) Corticosteroids incorporated into flexible collodion were applied on the lesion. [4] The influence of vehicles in the percutaneous absorption and thera peutic efficacy of corticosteroids was investigated by m any authors [1,5], After having established th at dimethylsulfoxyde enhances the ability of various chemicals to penetrate the stratum corneum and to form a lasting reservoir in it, this agent was added to corticosteroids to prolong their therapeutic effectiveness [6].To facilitate the dispersion and to produce widespread local effect hyalorunidase was added to intracutaneous injections of cortico steroids [8]. …”

mentioning

confidence: 99%